INNT vs. SCPS, EVLO, ONCSQ, AEHAW, GRFS, LVTX, MYNZ, NLSP, PHVS, and PROC
Should you be buying Innovate Biopharmaceuticals stock or one of its competitors? The main competitors of Innovate Biopharmaceuticals include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), OncoSec Medical (ONCSQ), Aesther Healthcare Acquisition (AEHAW), Grifols (GRFS), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), Pharvaris (PHVS), and Procaps Group (PROC).
Scopus BioPharma (NASDAQ:SCPS) and Innovate Biopharmaceuticals (NASDAQ:INNT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, community ranking, analyst recommendations, valuation and institutional ownership.
5.9% of Innovate Biopharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 7.9% of Innovate Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Innovate Biopharmaceuticals had 8 more articles in the media than Scopus BioPharma. MarketBeat recorded 8 mentions for Innovate Biopharmaceuticals and 0 mentions for Scopus BioPharma. Innovate Biopharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.
Innovate Biopharmaceuticals received 201 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 65.48% of users gave Innovate Biopharmaceuticals an outperform vote.
Scopus BioPharma has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Innovate Biopharmaceuticals has a beta of -0.39, indicating that its share price is 139% less volatile than the S&P 500.
Summary
Scopus BioPharma and Innovate Biopharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.
Get Innovate Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innovate Biopharmaceuticals Competitors List
Related Companies and Tools
Free INNT Stock Alerts